The Albert Einstein Cancer Center (AECC) in Bronx, New York, has announced the appointment of three faculty members to key leadership positions, reflecting the center’s commitment to basic science, translational, and clinical research and its core principles of diversity, equity, and inclusion.
New Deputy Director
Blood cancer researcher Ulrich Steidl, MD, PhD, has been named Deputy Director of AECC, responsible for overseeing the full spectrum of basic cancer research. He will focus on ensuring the strategic scientific priorities of the cancer center and work with Edward Chu, MD, MMS, Director of AECC, in facilitating connections between clinicians and scientists across Einstein and Montefiore to address urgent questions and discover solutions that will improve the health in the Bronx community and beyond.
Dr. Steidl is Co-Director of AECC’s Blood Cancer Institute and has held important leadership positions in the cancer center for several years. In 2021, Dr. Steidl received the Outstanding Investigator Award from the National Cancer Institute and a 7-year, $7 million grant for his research. He is best known for his work on myelodysplastic syndromes and acute myeloid leukemia (AML).
Dr. Steidl is Professor of Cell Biology and of Medicine, Interim Director for the Ruth L. and David S. Gottesman Institute for Stem Cell Biology and Regenerative Medicine, and holds the Rose C. Falkenstein Chair in Cancer Research at Einstein.
Inaugural Associate Director for Diversity, Equity, and Inclusion
Adebola Adedimeji, PhD, MBA, MPH, MS, has been appointed AECC’s first Associate Director for Diversity, Equity, and Inclusion (DEI). In his new role, Dr. Adedimeji will infuse DEI considerations into all aspects of the cancer center.
A social epidemiologist with additional training in business administration, Dr. Adedimeji’s research focuses on the social and structural factors that influence health with the goal of improving the well-being of historically marginalized communities.
Dr. Adedimeji is Research Associate Professor, Head of the Division of Health Behavior Research and Implementation Science, and Director for DEI in the Department of Epidemiology and Population Health at Einstein.
Emphasizing Equity in Cancer Epidemiology
H. Dean Hosgood, PhD, has been named Co-Leader of AECC’s Cancer Epidemiology, Prevention, and Control Research Program. Along with Co-Leader Bruce Rapkin, PhD, Dr. Hosgood will focus on population health research in the Bronx, improving resources that connect researchers to community partners and advocates and addressing the barriers to health equity.
Dr. Hosgood’s research focuses on how genetics and environmental exposures interact to cause cancer. He has worked extensively on investigating the causes of lung cancer in never-smokers, as well as blood cancers, including multiple myeloma and non-Hodgkin lymphoma. He is currently leading a global consortium to investigate how indoor air pollutants are associated with lung cancer mortality and result in an increased risk for other cancers.
Dr. Hosgood is Associate Professor of Epidemiology and Population Health, Director of Global Environmental Health in Einstein’s Global Health Center, Associate Director of Population and Clinical Sciences for Einstein’s Clinical Research Training Program, and Co-Director of Einstein’s PhD Program in Clinical Investigation.
